StockData
Lineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc. (LCTX) stock

LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)

Close on Nov 17, 2026Market cap $206.32MP/E –Yield –

Lineage Cell Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Lineage Cell Therapeutics's total debt was $18.00K at Dec 31, 2017. For fiscal 2017 it was $18.00K, down 85.0% from the year before. The highest annual figure on record is $246.00K in fiscal 2015.

Annual total debt

PeriodPeriod endValueChange
FY2017Dec 31, 2017$18.00K-85.0%
FY2016Dec 31, 2016$120.00K-51.2%
FY2015Dec 31, 2015$246.00K+693.5%
FY2014Dec 31, 2014$31.00K–
FY2013Dec 31, 2013$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2017Dec 31, 2017$18.00K-85.0%
Q3 FY2017Sep 30, 2017$44.00K-74.6%
Q2 FY2017Jun 30, 2017$95.00K–
Q1 FY2017Mar 31, 2017$95.00K–
Q4 FY2016Dec 31, 2016$120.00K–
Q3 FY2016Sep 30, 2016$173.00K–

More Lineage Cell Therapeutics figures

See a number that looks wrong?